The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

Shares of GSK PLC GSK rose 1.02% to £14.30 Wednesday, on what proved to be an all-around positive trading session for the ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...